Orforglipron Product Information
Orforglipron is a GLP-1 weight loss tablet being developed by Eli Lilly as an alternative to injectable weight loss pens such as Wegovy or Mounjaro.
How does Orforglipron work?
Orforglipron works by mimicking a natural hormone called glucagon-like peptide-1 (GLP-1), which is released in the gut after eating.
By activating the GLP-1 receptors, Orforglipron supports weight loss by:
- reducing appetite
- increasing feelings of fullness
- slowing gastric emptying, allowing food to remain in the stomach for longer
- regulating insulin and glucagon release, helping to improve blood sugar control
As a result, taking Orforglipron can help patients eat less and feel fuller after meals, supporting a sustained calorie deficit and promoting weight loss when used alongside a calorie-controlled diet and regular exercise.
How effective is Orforglipron for weight loss?
In the Phase 2 trial, patients taking Orforglipron lost, on average, between 8.6% and 12.6% of their body weight after 26 weeks of treatment, compared to only ~2% weight loss in the placebo group. By week 36 of treatment, the average body weight loss increased to between 9.4% to 14.7% with Orforglipron (compared to ~2.3% with placebo).
Pivotal Phase 3 trials have reported significant long-term weight loss. In one Phase 3 trial, participants titrating up to the highest daily dose (36 mg) of Orforglipron lost about 10.5% of their initial body weight (~10.4 kg) after 72 weeks of treatment.
When will Orforglipron be available in the UK?
Orforglipron is not yet available or approved in the UK, as it is still undergoing clinical trials.
Eli Lilly, the manufacturer, is expected to submit Orforglipron for regulatory approval in late 2025 or early 2026. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) would need to evaluate and approve the drug before it can become available.
If approved by the MHRA, Orforglipron could become available in the UK in 2026.
How does Orforglipron compare to Wegovy or Mounjaro?
Although Orforglipron is still in clinical development, early findings indicate that it may provide an effective and convenient oral tablet for weight management, offering an alternative to injectable treatments such as Wegovy and Mounjaro.
During Phase 3 clinical studies, patients lost an average of 10.5% of their body weight after taking Orforglipron for more than 72 weeks. In comparison, some clinical trials showed patients taking Wegovy (Semaglutide) lost up to 17% of their body weight over 68 weeks, while Mounjaro (Tirzepatide) patients lost 22.5% of their body weight over 72 weeks.
However, further clinical trials are needed to evaluate the effectiveness of Orforglipron as a long-term weight-loss treatment.
Who makes Orforglipron?
Orforglipron is manufactured by Eli Lilly, the same pharmaceutical company that produces Mounjaro (tirzepatide), which is currently one of the most effective weight-loss treatments available in the UK.
Is Orforglipron available in the UK?
Orforglipron is not yet approved as a weight loss treatment in the UK, as it is still undergoing clinical trials.
It may become available in the UK in 2026, depending on the regulatory approval.
How much weight can you lose with Orforglipron?
In a Phase 2 trial, patients lost an average of 9.4% to 14.7% of their body weight over 36 weeks, depending on the dose. Individual results may vary based on factors such as diet, lifestyle and treatment tolerance.
Where can I buy Orforglipron in the UK?
Orforglipron is not available for purchase in the UK at the moment as it is pending approval by the Medicines and Healthcare products Regulatory Agency (MHRA).